@article{ajidm2015342,
author={Timilsina, Mr. Suraj},
title={Activity of Linezolid against Multidrug-resistant Gram Positive Cocci in Eastern Nepal},
journal={American Journal of Infectious Diseases and Microbiology},
volume={3},
number={4},
pages={129--133},
year={2015},
url={http://pubs.sciepub.com/ajidm/3/4/2},
issn={2328-4064},
abstract={<b>Background:</b> The emergence of resistance in gram-positive bacteria has necessitated a search for new antimicrobial agents. Linezolid, an oxazolidinone, is a new class of antibacterial agents with enhanced activity against pathogens. <b>Method: </b>The in-vitro activity of linezolid was assessed against 461 gram-positive cocci; 301 <i>Staphylococcus</i> spp., 150 <i>Enterococcus</i> spp., 5 <i>Streptococcus pneumoniae</i> and 5 <i>Streptococcus pyogenes</i>, with an emphesis on testing multidrug-resistant isolates. <b>Results:</b> Linezolid demonstrated potent activity against all the isolates tested at the susceptible breakpoint (¡Ü4¦Ìg/ml). Against methicillin-resistant staphylococci and vancomycin-resistant enterococci, linezolid was the most active agent tested. Moreover, among 29.90% methicillin-resistant staphylococcal isolates, 20 exhibited intermediate susceptibility to vancomycin. Similarly, among the enterococcal isolates, 32% exhibited high level gentamicin-resistance whereas 7.33% were found to be vancomycin-resistant. None of the streptococcal isolates exhibited resistance to any of the antimicrobials tested. <b>Conclusions:</b> In summary, linezolid may represent an important therapeutic option for the treatment of infections caused by gram-positive cocci in Nepal.},
doi={10.12691/ajidm-3-4-2}
publisher={Science and Education Publishing}
}